Risk-Stratified Follow-Ups are gaining support because glaucoma suspect risk is not evenly spread across patients. For athletes, coaches, and active adults, the practical concern is simple: vision checks need to be frequent enough to catch meaningful change, but not so frequent that low-risk people face unnecessary appointment burdens. The strongest recent evidence points toward a middle path based on age, intraocular pressure, family history, structural findings, and documented change over time.
Glaucoma suspect status is not a diagnosis of glaucoma. It means an eye-care professional has seen findings that may raise concern, such as optic nerve appearance, eye pressure, family history, or visual field results. The studies below do not tell any one reader how often to be seen. They do show why a single follow-up schedule for every suspect can miss major differences in risk.
Why Risk-Stratified Follow-Ups Matter
Risk-Stratified Follow-Ups And Conversion Signals
A large U.S. retrospective cohort studied 83,305 patients diagnosed with open-angle glaucoma suspect between 2007 and 2021. Over five years, 20.6% converted to primary open-angle glaucoma. The annual conversion rate was 6.1%, with 9.4% in year 1 and 5.3% in years 2 through 5, according to the PubMed record. Those averages matter, but the spread behind them matters more.
In that same U.S. analysis, the lowest-risk group was younger than 50 and untreated. That group had an annual conversion rate of about 2.0%, with follow-ups around every 0.9 years on average. The highest-risk group was older than 70 and treated; its annual conversion rate was about 16.7%, with monitoring about every 0.4 years after the first year. That gap is too wide to ignore.
Risk-Stratified Follow-Ups do not mean guessing who is safe and who is not. They mean using observed risk factors to decide whether a person’s monitoring interval should be shorter, standard, or longer. In sports language, it is closer to workload management than benching someone without evidence. The plan changes when the data change.
What The Singapore Cohort Added
A Singapore tertiary eye centre cohort followed 101 glaucoma suspects for five years ending in mid-2025. The cumulative incidence of conversion to glaucoma was 17.8% at one year, 22.3% at two years, 23.0% at three years, 25.6% at four years, and 25.6% at five years, as reported in Eye. The study also identified independent predictors: family history, intraocular pressure above 21 mmHg, and age above 75 years.
The reported hazard ratios in that Singapore cohort were substantial: family history had a hazard ratio of 6.46, intraocular pressure of 22–24 mmHg had a hazard ratio of 8.60, pressure above 24 mmHg had a hazard ratio of 22.36, and age above 75 years had a hazard ratio of 6.28. These figures came from a relatively small tertiary-care cohort, so they should not be treated as universal estimates for every clinic. They do, however, align with the broader idea that risk is layered, not flat.
How Risk Signals Change Monitoring Choices
Age, Pressure, And Family History
Age, intraocular pressure, and family history appear repeatedly in the 2025–2026 evidence. These are not the only factors, but they are practical anchors. A younger untreated suspect with stable findings may not need the same cadence as an older suspect with higher pressure and a strong family history. That distinction can help clinics protect appointment access for people with the highest likelihood of change while keeping lower-risk patients under watch.
Guideline frameworks in 2025 and 2026 also moved in this direction. The European Glaucoma Society’s 6th edition, first published on September 8, 2025, listed re-evaluation every 12–24 months for low-risk primary open-angle glaucoma suspects and every 6–12 months for high-risk suspects. The factors listed in that guidance included intraocular pressure, family history, central corneal thickness, disc size, lens status, and pseudoexfoliation.
Structural And Field Clues Need Caution
Structural and functional measures can refine risk, but they also add interpretation challenges. Research discussed in 2026 connected microvascular dropout and beta-zone parapapillary atrophy changes in glaucoma suspect eyes with a higher risk of structural optic-disc progression, especially when both features were present. Other research found that eyes with faster visual field decline before a first progression event had a higher recurrence rate than slower progressors.
These findings support closer attention to optic nerve structure and visual field trajectory, but they are not stand-alone screening tools for the public. Imaging quality, test reliability, baseline anatomy, myopia, corneal thickness, and clinic setting can all influence interpretation. For readers comparing their own results, the safer takeaway is that repeated measurements over time often provide more useful information than a single number.
What This Means For Athletes And Communities
Training Culture And Appointment Culture
Athletes often understand monitoring better than they think. A coach does not assign the same recovery load to every runner after a hard interval session. The same logic applies to eye health follow-up: risk level shapes the schedule. Missing visits can be more consequential for someone with higher pressure, older age, family history, or early change than for someone with stable, low-risk findings.
That message has community value beyond elite sport. Recreational athletes, parents driving teenagers to practice, and older adults balancing work with medical visits all face time costs. Local information networks, including related public-interest sites such as Illinois Energy, show how practical community messaging can reach readers outside clinic walls. Eye health communication needs that same plain-language approach: clear risk factors, clear follow-up expectations, and no false certainty.
For readers who want a related discussion of how monitoring can be sorted by risk, our prior explainer on glaucoma suspect monitoring covers similar decision points without treating risk categories as fixed labels.
Limits Of The Evidence
Why The Numbers Should Not Be Overread
The U.S. cohort was large, but it was retrospective. That means the investigators studied existing records rather than assigning follow-up schedules in a controlled trial. Treated patients may have been treated because clinicians already believed they were higher risk, which can complicate comparisons. The Singapore cohort added detailed risk-factor findings, but it was small and came from a tertiary eye centre, where patient profiles may differ from general community practice.
Definitions of conversion also matter. A diagnosis code, optic nerve change, visual field shift, or clinician judgment may not capture the same event in every setting. Follow-up frequency can also affect detection: people seen more often have more chances for change to be documented. That does not make the findings weak; it means the results should guide careful monitoring plans rather than rigid rules.
Risk-Stratified Follow-Ups For Glaucoma Suspects
Risk-Stratified Follow-Ups are best understood as a decision framework, not a promise that disease will or will not develop. Based on the research supplied, a cautious framework would separate suspects by stable low-risk features, higher-risk baseline features, and evidence of change over time.
- Lower-risk suspects: younger age, no treatment, stable tests, and no strong risk signals may fit longer intervals discussed in recent guidance, if their clinician agrees.
- Higher-risk suspects: older age, higher intraocular pressure, family history, thin corneas, suspicious disc features, or pseudoexfoliation may justify shorter intervals.
- Changing findings: visual field decline, optic nerve structural progression, or uncontrolled pressure should prompt a recheck of the monitoring plan rather than waiting for a routine cycle.
For a sports community, the lesson is practical. Eye health success is not only about reacting after vision problems affect performance. It is also about matching surveillance to risk, keeping appointments realistic, and asking clinicians what specific findings place a person in a lower or higher follow-up category. That approach respects both the evidence and the uncertainty that still remains.